Literature DB >> 28539767

Serum erythropoietin levels in patients with central serous chorioretinopathy.

Burak Turgut1, Nevin Ilhan2, Fatma Yayla Uyar1, Ulku Celiker1, Tamer Demir1, Suleyman Serdar Koca3.   

Abstract

OBJECTIVE: To evaluate the levels of erythropoietin (EPO) in the serum in patients with central serous chorioretinopathy (CSC).
METHODS: An institutional comperative clinical study. The serum EPO levels were measured with the enzyme-linked immunosorbent assay (ELISA) method, of 15 patients with active CSC (Group 1), 15 patients with inactive CSC (Group 2) and 15 healthy volunteers (Group 3). Kruskal-Wallis variance analysis and Mann-Whitney U test were used for statistical analysis.
RESULTS: The patient and control groups were matched for age and sex. There was no statistically significant variation with regard to age and gender among the groups (P > 0.05). The mean serum EPO concentrations in patients with active CSC (Group 1), inactive CSC (Group 2) and in healthy controls (Group 3) were 11.39 ± 3.01 mlU/mL, 11.79 ± 3.78 mlU/mL and 11.95 ± 3.27 mlU/mL, respectively. There was no significant variation among the serum EPO concentrations of the study groups (P > 0.05).
CONCLUSION: These findings suggest no role of serum EPO in pathogenesis of CSC.

Entities:  

Keywords:  Central serous chorioretinopathy; erythropoietin; serum

Year:  2010        PMID: 28539767      PMCID: PMC5436175          DOI: 10.2147/eb.s10918

Source DB:  PubMed          Journal:  Eye Brain        ISSN: 1179-2744


  41 in total

Review 1.  Oxidative damage and protection of the RPE.

Authors:  J Cai; K C Nelson; M Wu; P Sternberg; D P Jones
Journal:  Prog Retin Eye Res       Date:  2000-03       Impact factor: 21.198

Review 2.  Hemodynamic effects of recombinant human erythropoietin.

Authors:  M Buemi; A Allegra; C Aloisi; F Corica; N Frisina
Journal:  Nephron       Date:  1999-01       Impact factor: 2.847

Review 3.  Effects of erythropoietin on brain function.

Authors:  W Jelkmann
Journal:  Curr Pharm Biotechnol       Date:  2005-02       Impact factor: 2.837

4.  Indocyanine green angiography of central serous chorioretinopathy.

Authors:  K Hayashi; Y Hasegawa; T Tokoro
Journal:  Int Ophthalmol       Date:  1986-04       Impact factor: 2.031

5.  Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE.

Authors:  Janet R Sparrow; Jilin Zhou; Shimon Ben-Shabat; Heidi Vollmer; Yasuhiro Itagaki; Koji Nakanishi
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-04       Impact factor: 4.799

6.  Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Authors:  Lichun Zhong; John Bradley; William Schubert; Ednan Ahmed; Anthony P Adamis; David T Shima; Gregory S Robinson; Yin-Shan Ng
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

Review 7.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

8.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Authors:  Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

9.  Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.

Authors:  Kyoung-Han Kim; Gavin Y Oudit; Peter H Backx
Journal:  J Pharmacol Exp Ther       Date:  2007-10-10       Impact factor: 4.030

Review 10.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.